N/A
N=339,902
Active Bathing to Eliminate Infection (ABATE Infection) Trial
Healthcare Associated Infections · Methicillin Resistant Staphylococcus Aureus · Multi Drug Resistant Organisms
Bottom Line
View on ClinicalTrials.gov: NCT02063867 ↗Enrolled (actual)
339,902
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcome: Primary: MRSA and VRE Clinical Cultures — 0.87; 0.79 Hazard Ratio (Intervention vs Baseline) — p=0.17
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Arm 2: Decolonization (Drug)
- Age
- Pediatric, Adult, Older Adult · 12+ yrs
- Sex
- All
- Sponsor
- University of California, Irvine
- Primary completion
- Feb 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY MRSA and VRE Clinical Cultures |
0.87; 0.79 | 0.17 |
| SECONDARY Gram-negative Multi-drug Resistant Organism Clinical Cultures |
0.81; 0.91 | 0.16 |
| SECONDARY All-cause Bloodstream Infections |
0.96; 0.90 | 0.43 |
Summary
The ABATE Infection Project is a cluster randomized trial of hospitals to compare two quality improvement strategies to reduce multi-drug resistant organisms and healthcare-associated infections in non-critical care units. The two strategies to be evaluated are:
* Arm 1: Routine Care Routine policy for showering/bathing
* Arm 2: Decolonization Use of chlorhexidine as routine soap for showering or bed bathing for all patients Mupirocin x 5 days if MRSA+ by history, culture, or screen
Note that enrolled "subjects" represents 53 individual HCA Hospitals (representing ~190 non-critical care units) that have been randomized.
Eligibility Criteria
Inclusion Criteria
- All HCA hospitals that reside in the United States
- Note: Unit of randomization is the hospital, but the participants are hospital units
Exclusion Criteria
- Non-critical care units where chlorhexidine bathing or decolonization for MRSA+ non-critical care patients is routine
- Pediatric, peri-partum, rehabilitation, psychiatry, and BMT units
- Units with >30% cardiac or hip/knee orthopedic surgeries
- Unit average length of stay <2 days
- Patients <12 years-old
- Patients with known allergy to mupirocin or chlorhexidine
Data sourced from ClinicalTrials.gov (NCT02063867). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.